osimertinib
astrazeneca
['lcsm,(-blcsm)', 'lung', 'osimertinib']
presented at #asco22 -- helpful chart to compare current results from some of the clinical trial options available to post-osimertinib progression. #asco22 #lcsm #egfr #lungcancer 
Co-Founder, @EGFRResisters LC Patient Group; writer for https://t.co/W6HLnN0ibZ; lc advocate/survivor; dx stage IV 2013
https://t.co/2UwibVmlPs